Skip to main content

Viridian Therapeutics, Inc.

VRDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001590750

In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Viridian Therapeutics, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of VRDN: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders135128−7
Shares43.1M47.1M+4.05M (+9.4%)
Value$1.10B$1.12B+$25.4M (+2.3%)

New holders (17)

Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to VRDN in Q2 2023
InstitutionSharesValue% of portfolio
Braidwell LP1,206,300$28.7M0.94%
PFM Health Sciences, LP293,140$6.97M0.28%
MPM Oncology Impact Management LP255,323$6.07M1.22%
Ally Bridge Group (NY) LLC201,752$4.80M5.81%
Soleus Capital Management, L.P.34,000$808.9K0.09%
Alps Advisors Inc31,707$754.3K0.01%
Knights of Columbus Asset Advisors LLC28,730$683.5K0.06%
Schonfeld Strategic Advisors LLC23,367$555.9K0.00%
Two Sigma Investments, LP21,018$500.0K0.00%
Man Group plc20,400$485.3K0.00%
DCF Advisers, LLC19,000$452.0K0.31%
Hennion & Walsh Asset Management, Inc.14,305$340.0K0.02%
First Trust Advisors LP11,992$285.3K0.00%
Occudo Quantitative Strategies LP9,720$231.2K0.02%
Two Sigma Advisers, LP9,500$226.0K0.00%
Aigen Investment Management, LP9,419$224.1K0.03%
Group One Trading, L.P.6,462$153.7K0.01%

Sold out (24)

Institutions that held Viridian Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.